SCHEDULE 13G: SCHEDULE 13G – Description

• Post author:andrewkaretas
• Post published:May 13, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G: SCHEDULE 13G – Description

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:May 9, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:May 9, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

“Off-the-shelf” CAR T – New frontiers in autoimmune disease

• Post author:andrewkaretas
• Post published:May 7, 2025
• Post category:Perspectives

Continue Reading“Off-the-shelf” CAR T – New frontiers in autoimmune disease

May 13, 2025 5:00 PM EDT : The Allogene Therapeutics First Quarter 2025 Conference Call

• Post author:andrewkaretas
• Post published:May 6, 2025
• Post category:Events

Continue ReadingMay 13, 2025 5:00 PM EDT : The Allogene Therapeutics First Quarter 2025 Conference Call

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

• Post author:andrewkaretas
• Post published:May 6, 2025
• Post category:Latest News

Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics…

Continue ReadingAllogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

DEFA14A: Additional proxy soliciting materials – definitive

• Post author:andrewkaretas
• Post published:April 30, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingDEFA14A: Additional proxy soliciting materials – definitive

ARS: An annual report to security holders

• Post author:andrewkaretas
• Post published:April 30, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingARS: An annual report to security holders

DEF 14A: Official notification to shareholders of matters to be brought to a vote (“Proxy”)

• Post author:andrewkaretas
• Post published:April 30, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingDEF 14A: Official notification to shareholders of matters to be brought to a vote (“Proxy”)

4: Statement of changes in beneficial ownership of securities

• Post author:andrewkaretas
• Post published:April 23, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities